Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study

BACKGROUND: Neoadjuvant therapy has significantly improved the 5-year overall survival (OS) of patients with resectable non-small cell lung cancer (NSCLC). The CheckMate 159 trial showed that neoadjuvant therapy with a single-drug programmed cell death protein 1 (PD-1) inhibitor (nivolumab) achieved...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Transl Lung Cancer Res
Glavni autori: Duan, Hongtao, Wang, Tianhu, Luo, Zhilin, Tong, Liping, Dong, Xiaoping, Zhang, Yong, Afzal, Muhammad Zubair, Correale, Pierpaolo, Liu, Honggang, Jiang, Tao, Yan, Xiaolong
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2021
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7947385/
https://ncbi.nlm.nih.gov/pubmed/33718040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-21-130
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items